Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras

Biomaterials

Volumn 35, Issue 9, 2014, Pages 2905-2914

  Lai, Wei Yun ^a,b,c   Wang, Wei Ya ^c   Chang, Yi Chung ^c   Chang, Cheng Ju ^c   Yang, Pan Chyr ^c,d   Peck, Konan ^c  

^a ACADEMIA SINICA   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Aptamer; Combination therapy; Lung cancer; Metastasis; SiRNA

Indexed keywords

APTAMER; COMBINATION THERAPY; LUNG CANCER; METASTASIS; SIRNA;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; PHOSPHOPROTEINS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894952867     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.054     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009, 59:225-249.
2. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. NEngl J Med 2008, 359:1367-1380.
3. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010, 10:760-774.
4. Temel J.S., Greer J.A., Muzikansky A., Gallagher E.R., Admane S., Jackson V.A., et al. Early palliative care for patients with metastatic non-small-cell lung cancer. NEngl J Med 2010, 363:733-742.
5. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
6. Bacac M., Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol 2008, 3:221-247.
7. Shih J.Y., Tsai M.F., Chang T.H., Chang Y.L., Yuan A., Yu C.J., et al. Transcription repressor Slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res. 2005, 11:8070-8078.
8. Hong T.M., Chen Y.L., Wu Y.Y., Yuan A., Chao Y.C., Chung Y.C., et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res. 2007, 13:4759-4768.
9. Wang S.P., Wang W.L., Chang Y.L., Wu C.T., Chao Y.C., Kao S.H., et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol. 2009, 11:694-704.
10. Kao S.H., Wang W.L., Chen C.Y., Chang Y.L., Wu Y.Y., Wang Y.T., et al. GSK3beta controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug. Oncogene 2013, Available from: URL:. http://dx.doi.org/10.1038/onc.2013.279.
11. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428.
12. Shih J.Y., Yang P.C. The EMT regulator Slug and lung carcinogenesis. Carcinogenesis 2011, 32:1299-1304.
13. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
14. Ellis L.M. The role of neuropilins in cancer. Mol Cancer Ther 2006, 5:1099-1107.
15. Jarvis A., Allerston C.K., Jia H., Herzog B., Garza-Garcia A., Winfield N., et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. JMed Chem. 2010, 53:2215-2226.
16. Nimjee S.M., Rusconi C.P., Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu Rev Med 2005, 56:555-583.
17. Zhou J., Rossi J.J. Aptamer-targeted cell-specific RNA interference. Silence 2010, 1:4.
18. Neff C.P., Zhou J.H., Remling L., Kuruvilla J., Zhang J.N., Li H.T., et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 2011, 3:66ra6.
19. Wheeler L.A., Trifonova R., Vrbanac V., Basar E., McKernan S., Xu Z., et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. JClin Invest 2011, 121:2401-2412.
20. Wheeler L.A., Vrbanac V., Trifonova R., Brehm M.A., Gilboa-Geffen A., Tanno S., et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther 2013, 21:1378-1389.
21. Wang C.W., Chung W.H., Cheng Y.F., Ying N.W., Peck K., Chen Y.T., et al. Anew nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. JAllergy Clin Immunol 2013, 132:713-722.e11.
22. Dassie J.P., Liu X.Y., Thomas G.S., Whitaker R.M., Thiel K.W., Stockdale K.R., et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009, 27:839-849.
23. Hussain A.F., Tur M.K., Barth S. An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing alphavbeta3 integrin. Nucleic Acid Ther 2013, 23:203-212.
24. Ni X., Zhang Y., Ribas J., Chowdhury W.H., Castanares M., Zhang Z., et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. JClin Invest 2011, 121:2383-2390.
25. Pastor F., Kolonias D., Giangrande P.H., Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010, 465:227-230.
26. Thiel K.W., Hernandez L.I., Dassie J.P., Thiel W.H., Liu X.Y., Stockdale K.R., et al. Delivery of chemo-sensitizing siRNAs to HER2(+)-breast cancer cells using RNA aptamers. Nucleic Acids Res. 2012, 40:6319-6337.
27. Zhou J., Tiemann K., Chomchan P., Alluin J., Swiderski P., Burnett J., et al. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res. 2013, 41:4266-4283.
28. Lee J.F., Hesselberth J.R., Meyers L.A., Ellington A.D. Aptamer database. Nucleic Acids Res. 2004, 32:D95-D100.
29. Ireson C.R., Kelland L.R. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006, 5:2957-2962.
30. Bates P.J., Laber D.A., Miller D.M., Thomas S.D., Trent J.O. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009, 86:151-164.
31. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
32. Nicklas J.A., Buel E. Development of an Alu-based, real-time PCR method for quantitation of human DNA in forensic samples. JForensic Sci. 2003, 48:936-944.
33. Choi W.W., Lewis M.M., Lawson D., Yin-Goen Q., Birdsong G.G., Cotsonis G.A., et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005, 18:143-152.
34. Lao Y.H., Peck K., Chen L.C. Enhancement of aptamer microarray sensitivity through spacer optimization and avidity effect. Anal Chem. 2009, 81:1747-1754.
35. Tom J.K., Mancini R.J., Esser-Kahn A.P. Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation. Chem Commun (Camb) 2013, 49:9618-9620.
36. Mattila P.K., Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008, 9:446-454.
37. Mayer G. The chemical biology of aptamers. Angew Chem Int Ed Engl 2009, 48:2672-2689.
38. Mak P., Leav I., Pursell B., Bae D., Yang X., Taglienti C.A., et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated Snail nuclear localization: implications for Gleason grading. Cancer Cell. 2010, 17:319-332.
39. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009, 15:232-239.
40. Perez-Losada J., Sanchez-Martin M., Perez-Caro M., Perez-Mancera P.A., Sanchez-Garcia I. The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug. Oncogene 2003, 22:4205-4211.
41. Jia H., Cheng L., Tickner M., Bagherzadeh A., Selwood D., Zachary I. Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. Br J Cancer 2010, 102:541-552.
42. Chang T.H., Tsai M.F., Su K.Y., Wu S.G., Huang C.P., Yu S.L., et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med 2011, 183:1071-1079.
43. Catalano A., Rodilossi S., Rippo M.R., Caprari P., Procopio A. Induction of stem cell factor/c-Kit/Slug signal transduction in multidrug-resistant malignant mesothelioma cells. JBiol Chem. 2004, 279:46706-46714.
44. Zhang K., Chen D., Wang X., Zhang S., Wang J., Gao Y., et al. RNA interference targeting Slug increases cholangiocarcinoma cell sensitivity to cisplatin via upregulating PUMA. Int J Mol Sci. 2011, 12:385-400.
45. Mancini M., Petta S., Iacobucci I., Salvestrini V., Barbieri E., Santucci M.A. Zinc-finger transcription factor Slug contributes to the survival advantage of chronic myeloid leukemia cells. Cell Signal 2010, 22:1247-1253.
46. Vitali R., Mancini C., Cesi V., Tanno B., Mancuso M., Bossi G., et al. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models. Clin Cancer Res. 2008, 14:4622-4630.
47. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
48. Wang Y., Ngo V.N., Marani M., Yang Y., Wright G., Staudt L.M., et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010, 29:4658-4670.
49. Wey J.S., Gray M.J., Fan F., Belcheva A., McCarty M.F., Stoeltzing O., et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 2005, 93:233-241.
50. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011, 144:646-674.